|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From Mount Sinai Hospital (Dr. Grossman), Toronto, Canada; and North Shore University Hospital (Dr. Fein), Manhassett, NY.
Correspondence to: Ronald F. Grossman, MD, FCCP, Mount Sinai Hospital, Suite 640, 600 University Ave, Toronto, Ontario, Canada M5G 1X5; e-mail: ronaldf.grossman{at}utoronto.ca
| Introduction |
|---|
|
|
|---|
The PSB technique was developed in 1987 by Wimberly et al1 and has since been improved. Because it was found that samples may become contaminated by organisms of the upper airway, methods have been advanced to protect the sampling fluid. In addition, quantitative culture methods have been developed to permit distinguishing infection from colonization. However, because of concerns about diagnostic accuracy, reproducibility of results, diagnostic thresholds, nonstandardized methodology, and lack of data on clinical outcome, few definitive recommendations have been reached.2,3
The Health and Science Policy Committee of the American College of Chest Physicians assembled a panel of scientific experts to develop diagnostic recommendations based on a rigorous review of the literature. The panel included experienced methodologists to ensure that the review process was justifiable and unbiased. Recommendations were developed through group discussion and were based on direct evidence, when it was available, and expert consensus opinion, when direct evidence was not available.
To implement the evidence-based assessment, the panel adopted the following grading system for most recommendations:
This manuscript covers the following topic areas:
This executive summary reports the panelists major conclusions and final recommendations. The reader may assess the thoroughness of the evaluation process and the validity of the conclusions by reviewing each section.
| Epidemiology |
|---|
|
|
|---|
Nosocomial pneumonia is an intrahospital infection that develops
48
h after admission; VAP is a complication of intubation and mechanical
ventilator support. Early-onset VAP occurs during the first 4 days of
mechanical ventilation and often is caused by Streptococcus
pneumoniae, Haemophilus influenzae, or Moraxella
catarrhalis. Uncommonly, anaerobes are the causative agents.
Late-onset VAP develops
5 days after the initiation of mechanical
ventilation, and is commonly caused by Pseudomonas
aeruginosa, Acinetobacter or Enterobacter spp, or
methicillin-resistant Staphylococcus aureus.5
Each day the patient receives endotracheal intubation and mechanical ventilation, the crude rate of VAP increases by 1 to 3% and the risk of death increases twofold to 10-fold. When the causative pathogen is P aeruginosa, disease-specific (attributable) mortality may be as high as 43%.6 In addition, VAP is often associated with a dramatic increase in length of hospital stay and total hospital costs.7
| Radiologic Diagnosis |
|---|
|
|
|---|
In diagnosing VAP, the presence of alveolar infiltrates, determined by invasive techniques or by histologic studies, has a sensitivity of 58 to 83% for air bronchogram signs, and 50 to 78% for new or worsening infiltrates.8,9 Specificity is unknown, because reports do not state the appropriate denominator (ie, the number of patients receiving ventilator assistance who do not have pneumonia and who have normal findings on a chest radiograph).
The presence of any one radiographic sign does not significantly increase the likelihood of VAP, because other potential causes of radiographic abnormalities occur in ventilator-assisted patients.9 Chest radiographs are not a reliable diagnostic tool, as there is only marginal reproducibility of the findings obtained from two readers.10 Finally, the negative clinical and economic impacts of misinterpreting chest radiographs have not been evaluated.
| Clinical Criteria |
|---|
|
|
|---|
These findings suggest that the presence of abnormal clinical manifestations, combined with abnormal radiographic findings, can be used for the initial screening for VAP. However, the lack of specificity with this method suggests that additional procedures are needed, such as cultures of lower respiratory tract secretions (grade B recommendation).
| Role of Endotracheal Aspiration |
|---|
|
|
|---|
The results of quantitative cultures on specimens obtained by aspiration vary with the bacterial load, the duration of mechanical ventilation, and prior use of antimicrobial therapy. Sensitivity ranges from 38 to 100%, and specificity ranges from 14 to 100%.14,15 Antibody coating and the presence of elastin fibers are not diagnostically sensitive or specific for VAP.1618 A Grams stain and culture of endotracheal secretions obtained by aspiration may be useful in diagnosing VAP (grade D recommendation). The presence of antibody coating or elastin fibers is an unreliable indicator and is not recommended for clinical diagnostic use (grade C recommendation).
| Role of BAL |
|---|
|
|
|---|
The sensitivity of quantitative BAL fluid cultures ranges from 42 to 93%, with a mean of 73%. The variability reflects the characteristics of the study population, the prior administration of antibiotics (which reduces sensitivity), and the reference test used.20,21
For quantitative cultures, a finding of 103 to 105 cfu/mL is considered a positive result. Most studies cite 104cfu/mL as a positive result. Sensitivity varies inversely with the cutoff point. Similar problems exist in calculating specificity. When specificity could be accurately determined, it ranged from 45 to 100%, with a mean of 82%.22,23, The detection of intracellular organisms by BAL is highly specific (89 to 100%) and has a high positive predictive value, but is not highly sensitive (37 to 100%).18, 24
BAL is generally a safe procedure in patients with acute lung injury, some of whom have pneumonia. The major risk is the reduction of arterial oxygenation, as oxygenation may not be fully reestablished for several hours after injury.25
| Role of PSB Sampling |
|---|
|
|
|---|
One study has examined the reproducibility of PSB sampling.27 In 25% of cases, a single bronchial-brush determination led to a false positive or a false negative.
Specimens taken from an affected lobe have a much higher concentration of organisms than those taken from an unaffected lobe.
Sensitivity for PSB tests ranges from 33 to 100%,28,29 with a median of 67%. Specificity ranges from 50 to 100%, with a median of 95%. PSB sampling appears to be somewhat more specific than sensitive in diagnosing VAP. In all but one of the 18 studies reviewed, the diagnostic likelihood ratio in VAP was significantly > 1.
The complications of this procedure have not been determined. As noted above, bronchoscopy alone in a patient receiving ventilation may lead to transient alterations in oxygenation; it is not clear whether the PSB technique adds to the risk.
| Role of Blinded Invasive Procedures |
|---|
|
|
|---|
In BBS, a catheter is blindly wedged into a distal bronchus, and secretions are aspirated without the instillation of fluid. In mini-BAL, a sterile, single-sheathed, 50-cm, plugging, telescoping catheter usually is used, and 20 to 150 mL of BAL fluid is instilled. Sometimes an unprotected catheter is used instead. In BPSB, a sterile brush, protected from contamination, is used. None of these techniques have been standardized.
The sensitivity of these tests is as follows: BBS, 74 to 97%; mini-BAL, 63 to 100%2830; and BPSB, 58 to 86%.2831 Specificity of these tests is as follows: BBS, 74 to 100%; mini-BAL, 66 to 96%; and BPSB, 71 to 100%. These specificity ranges are similar to those reported for BAL and PSB. Unlike established invasive procedures, these newer techniques have not been validated in postmortem studies.
The risks from blinded techniques appear to be minimal and are no greater than those with fiberoptic bronchoscopy.
| Invasive Procedures in Nonresolving Pneumonia |
|---|
|
|
|---|
| Conclusion |
|---|
|
|
|---|
|
If two or more of these abnormalities are present, however, a chest radiograph should be evaluated. If the findings are normal, other causes of the abnormal clinical features should be investigated (grade C recommendation). If the radiograph shows alveolar infiltrates or an air bronchogram sign, or if the findings have worsened, the panel recommends one of two management options. The first option involves quantitative testing; and the second involves empirical treatment and nonquantitative (qualitative) testing.
In the first option, quantitative procedures include nonbronchoscopic techniques (quantitative endotracheal aspiration, BBS, mini-BAL, or BPSB) and bronchoscopic techniques (BAL, PSB, or protected BAL). Because these tests have similar sensitivities, specificities, positive predictive values, and likelihood ratios, the choice depends on local expertise, experience, availability, and cost factors (grade D recommendation). Treatment should be based on the results of diagnostic testing. Decisions about empirical therapy should be determined by the patients clinical stability, the degree of clinical suspicion, and the results of preliminary tests.
In the second option, the selection of appropriate empirical therapy is based on risk factors, local epidemiology, and resistance patterns, and involves qualitative testing to identify possible pathogens. Some clinicians include quantitative testing. Therapy is adjusted according to culture results or clinical response.
These two options are offered (grade D recommendation) because of insufficient high-level evidence to indicate that quantitative testing produces better clinical outcomes than empirical treatment. While invasive tests may avoid the use of antibiotics for clinically insignificant organisms, no direct evidence or consensus indicates the superiority of one invasive test over another (grade B recommendation). In a recent study, the withholding of antibiotic therapy when invasive tests did not confirm a clinical suspicion of VAP was not associated with the recurrence of VAP or with increased mortality rates.35 Factors to consider in choosing a test include sensitivity and specificity, ability to improve patient outcome, potential adverse effects, availability of the test, and cost. The panel did not determine whether the potential benefits of diagnostic testing outweigh the potential risks.
Substantial gaps exist in the scientific knowledge of all of these techniques. The best example is the lack of data on the specificity and reproducibility of findings from chest radiographs. Because many diagnostic techniques have not been standardized, reported data on sensitivity and specificity vary, and it is difficult to compare results between medical centers. Another problem is that the populations that have been studied have been very heterogeneous, and some studies have used only subsets of patients in order to make a specific point.
Many patients receive antimicrobial agents before testing is performed, making it difficult or impossible to interpret test results. Evidence suggests that after recent antibiotic treatment for suspected VAP, the diagnostic thresholds for numbers of organisms in the culture must be decreased to maintain accuracy.36 In contrast, ongoing antibiotic therapy for a preexisting infectious disease does not affect the diagnostic accuracy of PSB or BAL. Future studies should define patient populations more carefully, particularly with respect to the onset of antimicrobial therapy. It is possible that the variability of invasive testing would diminish and the test characteristics would improve if this analysis were standardized. A "gold standard" should be defined, since autopsy studies and studies of lung tissue obtained by biopsy are obviously impractical. The only randomized, prospective clinical trial comparing invasive techniques and noninvasive quantitative techniques in patients with VAP found that invasive techniques led to more frequent changes in antibiotic therapy but that they did not change the mortality rate.34
We recommend formal outcome research with randomized, controlled trials to assess various diagnostic and management strategies. This approach would provide the opportunity to evaluate economic outcomes using cost-benefit, cost-effectiveness, and cost-utility analyses.
| Footnotes |
|---|
This article has been cited by other articles:
![]() |
C. Clec'h, F. Jaureguy, L. Hamza, P. Karoubi, J.-P. Fosse, A. Hamdi, F. Vincent, F. Gonzalez, and Y. Cohen Agreement Between Quantitative Cultures of Postintubation Tracheal Aspiration and Plugged Telescoping Catheter, Protected Specimen Brush, or BAL for the Diagnosis of Nosocomial Pneumonia. Chest, October 1, 2006; 130(4): 956 - 961. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Afessa, R. D. Hubmayr, E. A. Vetter, M. T. Keegan, K. L. Swanson, L. M. Baddour, F. R. Cockerill III, and S. G. Peters Bronchoscopy in Ventilator-associated Pneumonia: Agreement of Calibrated Loop and Serial Dilution Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1229 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Leal-Noval, R. Amaya, A. Herruzo, A. Hernandez, A. Ordonez, A. Marin-Niebla, and P. Camacho Effects of a Leukocyte Depleting Arterial Line Filter on Perioperative Morbidity in Patients Undergoing Cardiac Surgery: A Controlled Randomized Trial Ann. Thorac. Surg., October 1, 2005; 80(4): 1394 - 1400. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Brun-Buisson, M. Fartoukh, E. Lechapt, S. Honore, J.-R. Zahar, C. Cerf, and B. Maitre Contribution of Blinded, Protected Quantitative Specimens to the Diagnostic and Therapeutic Management of Ventilator-Associated Pneumonia Chest, August 1, 2005; 128(2): 533 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ahrens, M. Kollef, J. Stewart, and W. Shannon Effect Of Kinetic Therapy on Pulmonary Complications Am. J. Crit. Care., September 1, 2004; 13(5): 376 - 382. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Ost, C. S. Hall, G. Joseph, C. Ginocchio, S. Condon, E. Kao, M. LaRusso, R. Itzla, and A. M. Fein Decision Analysis of Antibiotic and Diagnostic Strategies in Ventilator-associated Pneumonia Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1060 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Leroy, S. Jaffre, T. d'Escrivan, P. Devos, H. Georges, S. Alfandari, and G. Beaucaire Hospital-Acquired Pneumonia: Risk Factors for Antimicrobial-Resistant Causative Pathogens in Critically Ill Patients Chest, June 1, 2003; 123(6): 2034 - 2042. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Chinsky Ventilator-Associated Pneumonia: Is There Any Gold in These Standards? Chest, December 1, 2002; 122(6): 1883 - 1885. [Full Text] [PDF] |
||||
![]() |
S. Michaud, S. Suzuki, and S. Harbarth Effect of Design-related Bias in Studies of Diagnostic Tests for Ventilator-associated Pneumonia Am. J. Respir. Crit. Care Med., November 15, 2002; 166(10): 1320 - 1325. [Full Text] [PDF] |
||||
![]() |
O. Leroy, P. Giradie, Y. Yazdanpanah, H. Georges, S. Alfandari, V. Sanders, P. Devos, and G. Beaucaire Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Eur. Respir. J., August 1, 2002; 20(2): 432 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rello, J. A. Paiva, J. Baraibar, F. Barcenilla, M. Bodi, D. Castander, H. Correa, E. Diaz, J. Garnacho, M. Llorio, et al. International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-Associated Pneumonia Chest, September 1, 2001; 120(3): 955 - 970. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Sintchenko and G L Gilbert Evidence based diagnostic microbiology: has its time come? J. Clin. Pathol., June 1, 2001; 54(6): 441 - 442. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |